These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1845044)

  • 21. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus.
    Stott EJ; Almond N; Kent K; Walker B; Hull R; Rose J; Silvera P; Sangster R; Corcoran T; Lines J; Silvera K; Luciw P; Murphy-Corb M; Momin P; Bruck C
    J Gen Virol; 1998 Mar; 79 ( Pt 3)():423-32. PubMed ID: 9519819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
    Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
    Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.
    Pal R; Kalyanaraman VS; Nair BC; Whitney S; Keen T; Hocker L; Hudacik L; Rose N; Mboudjeka I; Shen S; Wu-Chou TH; Montefiori D; Mascola J; Markham P; Lu S
    Virology; 2006 May; 348(2):341-53. PubMed ID: 16460776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls.
    Sitz KV; Ratto-Kim S; Hodgkins AS; Robb ML; Birx DL
    J Infect Dis; 1999 Apr; 179(4):817-24. PubMed ID: 10068576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunization for long-term protection against AIDS using the macaque model.
    Kumar A; Narayan O
    Virology; 2001 Jun; 285(1):1-5. PubMed ID: 11414799
    [No Abstract]   [Full Text] [Related]  

  • 26. Potential risks of eliciting antibodies enhancing HIV-1 infection of monocytic cells by vaccination with V3 loops of unmatched HIV-1 isolates.
    Jiang S; Neurath AR
    AIDS; 1992 Mar; 6(3):331-2. PubMed ID: 1567580
    [No Abstract]   [Full Text] [Related]  

  • 27. CD4-independent infection of HIV and SIV: implications for envelope conformation and cell tropism in vivo.
    Bhattacharya J; Peters PJ; Clapham PR
    AIDS; 2003; 17 Suppl 4():S35-43. PubMed ID: 15080178
    [No Abstract]   [Full Text] [Related]  

  • 28. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1.
    Gohain N; Tolbert WD; Acharya P; Yu L; Liu T; Zhao P; Orlandi C; Visciano ML; Kamin-Lewis R; Sajadi MM; Martin L; Robinson JE; Kwong PD; DeVico AL; Ray K; Lewis GK; Pazgier M
    J Virol; 2015 Sep; 89(17):8840-54. PubMed ID: 26085162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GP120: target for neutralizing HIV-1 antibodies.
    Pantophlet R; Burton DR
    Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modern vaccines. Human immunodeficiency virus and AIDS: challenges and progress.
    Schild GC; Minor PD
    Lancet; 1990 May; 335(8697):1081-4. PubMed ID: 1970381
    [No Abstract]   [Full Text] [Related]  

  • 33. Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251.
    Lü X; Kiyono H; Lu D; Kawabata S; Torten J; Srinivasan S; Dailey PJ; McGhee JR; Lehner T; Miller CJ
    AIDS; 1998 Jan; 12(1):1-10. PubMed ID: 9456249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.
    Cho MW; Kim YB; Lee MK; Gupta KC; Ross W; Plishka R; Buckler-White A; Igarashi T; Theodore T; Byrum R; Kemp C; Montefiori DC; Martin MA
    J Virol; 2001 Mar; 75(5):2224-34. PubMed ID: 11160726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and analysis of recombinant BCG vector systems.
    Fuerst TR; de la Cruz VF; Bansal GP; Stover CK
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1451-5. PubMed ID: 1466980
    [No Abstract]   [Full Text] [Related]  

  • 36. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
    Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
    J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals.
    Wrin T; Nunberg JH
    AIDS; 1994 Nov; 8(11):1622-3. PubMed ID: 7848602
    [No Abstract]   [Full Text] [Related]  

  • 38. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
    Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.
    Burton DR; Pyati J; Koduri R; Sharp SJ; Thornton GB; Parren PW; Sawyer LS; Hendry RM; Dunlop N; Nara PL
    Science; 1994 Nov; 266(5187):1024-7. PubMed ID: 7973652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stimulation of HIV-1-neutralizing antibodies in simian HIV-IIIB-infected macaques.
    Müller S; Margolin DH; Nara PL; Alvord WG; Köhler H
    Proc Natl Acad Sci U S A; 1998 Jan; 95(1):276-81. PubMed ID: 9419366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.